Telix Pharmaceuticals Ltd. TLX 深 滬
已收盤 09-12 16:00:00 美东时间
9.21
-0.110
-1.18%
華盛通- 最 高9.24
- 今 開9.16
- 成交量 16.57万股
- 最 低 9.14
- 昨 收 9.32
- 總市值 30.85亿
- 52周最高 30.36
- 市盈率 靜 96.54
- 換手率 0.05%
- 52周最低 8.93
- 委 比 93.66%
- 總股本 3.35亿
- 歷史最高 30.36
- 量 比 0.74
- 振 幅 1.07%
- 歷史最低 8.93
- 每 手 1
- 風險率 2.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Challenger Limited Ceases Substantial Holding in Telix Pharmaceuticals
Telix Pharmaceuticals ( ($AU:TLX) ) has shared an announcement. Challenger Limi...
09-12 15:28
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (<sup>68</sup>Ga) gozetotide injection) to include prostate cancer diagnosis. BiPASS™ (<strong>Bi</strong>opsy of the <strong>P</strong...
09-09 23:00
Telix Pharmaceuticals and FDA Agree on Resubmission Pathway for TLX101-CDx
The latest announcement is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix ...
09-09 07:28
Telix Pharmaceuticals to Release Shares from Voluntary Escrow
An announcement from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Teli...
09-05 07:07
美股周涨跌榜 | 回声星通信涨108.6%，AT&T斥资230亿美元收购特定无线频谱许可证；MONGODB涨44.1%，Q2业绩超预期
回声星通信涨108.6%，AT&T斥资230亿美元收购特定无线频谱许可证；MONGODB涨44.1%，Q2业绩超预期，大行纷纷上调其目标价>>
08-30 10:35
JP Morgan Downgrades Telix Pharmaceuticals to Neutral
JP Morgan downgrades Telix Pharmaceuticals (NASDAQ:TLX) from Overweight to Neutral.
08-29 04:09
Telix Gets Second FDA Rejection For Kidney Cancer Drug
FDA sent a second CRL to Telix, delaying its kidney cancer PET drug. Analysts weigh pricing pressure, and growth opportunities.
08-29 01:08
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.
08-28 21:12
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Shares of Snowflake Inc. (NYSE:SNOW) rose sharply in pre-market trading after t...
08-28 17:48
